Next Article in Journal
Colorectal Cancer Screening in Canada: Results from the First Round of Screening for Five Provincial Programs
Previous Article in Journal
Isolated Late Metastasis from Testicular Seminoma Presenting as a Parotid Gland Mass: Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 5
10.3747/co.20.1370
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009

by
N. Bouganim
1,
A. Mamo
2,
D.W. Wasserman
1,
G. Batist
2,
P. Metrakos
3,
P. Chaudhury
3,
M. Hassanain
3 and
P. Kavan
1,2,*
1
Department of Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
2
Department of Oncology and Segal Cancer Centre, McGill University, Montreal, QC, Canada
3
Department of Surgery, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(5), 247-251; https://doi.org/10.3747/co.20.1370
Submission received: 5 July 2013 / Revised: 6 August 2013 / Accepted: 6 September 2013 / Published: 1 October 2013

Abstract

Background: Before its regulatory approval in Canada, bevacizumab to treat patients with colorectal cancer (CRC) was accessed through the Bevacizumab Expanded Access Trial and a special-access program at the Jewish General Hospital. We retrospectively evaluated patient outcomes in that large cohort. Methods: All patients (n = 196) had metastatic CRC, were bevacizumab-naïve, and received bevacizumab in combination with chemotherapy at the Jewish General Hospital between 2004 and 2009. We collected patient demographics and clinical characteristics; relevant medical history, disease stage and tumour pathology at diagnosis; type, duration, and line of therapy; grades 3 and 4 adverse events (AES), time to disease progression (TTP), and overall survival (OS) from diagnosis. Results: Median follow-up was 36.0 months. Median TTP was 8.0 months [95% confidence interval (CI): 7.0 to 9.0 months). Median OS was 41.0 months (95% CI: 36.0 to 47.0 months). Of the 40 grades 3 and 4 bevacizumabrelated AES experienced by 38 patients (19.4%), the most common were thrombocytopenia (n = 17), deep-vein thrombosis (n = 6), pulmonary embolism (n = 4), and hypertension (n = 3). Conclusions: In an expanded access setting, our data reflect the efficacy and safety of bevacizumab-based therapy in the controlled post-registration clinical trial setting.
Keywords: bevacizumab; colorectal cancer; efficacy; safety bevacizumab; colorectal cancer; efficacy; safety

Share and Cite

MDPI and ACS Style

Bouganim, N.; Mamo, A.; Wasserman, D.W.; Batist, G.; Metrakos, P.; Chaudhury, P.; Hassanain, M.; Kavan, P. Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. Curr. Oncol. 2013, 20, 247-251. https://doi.org/10.3747/co.20.1370

AMA Style

Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. Current Oncology. 2013; 20(5):247-251. https://doi.org/10.3747/co.20.1370

Chicago/Turabian Style

Bouganim, N., A. Mamo, D.W. Wasserman, G. Batist, P. Metrakos, P. Chaudhury, M. Hassanain, and P. Kavan. 2013. "Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009" Current Oncology 20, no. 5: 247-251. https://doi.org/10.3747/co.20.1370

APA Style

Bouganim, N., Mamo, A., Wasserman, D. W., Batist, G., Metrakos, P., Chaudhury, P., Hassanain, M., & Kavan, P. (2013). Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. Current Oncology, 20(5), 247-251. https://doi.org/10.3747/co.20.1370

Article Metrics

Back to TopTop